ContraVir leadership brings deep experience in the development and commercialization of targeted antiviral therapies for indications of important unmet need.
Robert Foster, B.Sc. (Pharm), Pharm.D., Ph.D.
Chief Executive Officer
Dr. Foster brings over 30 years of pharmaceutical and biotech experience to Contravir. Prior to Contravir, he was CEO and Founder of Ciclofilin Pharmaceuticals Inc. which merged with ContraVir. Prior to Ciclofilin Pharmaceuticals, he founded Isotechnika Pharma Inc. He was Chairman and CEO of Isotechnika (TSX:ISA) for 21 years. Dr. Foster was founding CEO, and later CSO, of Aurinia (NASDAQ:AUPH) after Isotechnika acquired Aurinia. During his tenure with Isotechnika, Dr. Foster, together with a core team, discovered the immunosuppressive drug voclosporin. Learn More >>
Chief Financial Officer
John Cavan brings more than 20 years of financial management experience in both public and private companies. Prior to joining ContraVir as CFO, Mr. Cavan was a consultant with The Pine Hill Group where he was instrumental in completing several financial transactions, including initial public offerings, business combinations and strategic transactions. Prior to his role with the Pine Hill Group, he served as Chief Accounting Officer at Stemline Therapeutics, Inc. receding his role at Stemline, Mr. Cavan was Vice President and Chief Accounting Officer at Aegerion Pharmaceuticals. Learn More >>